Natco Pharma Ltd
Natco Pharma Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects a good year ahead with strong growth this and next year, despite volatility related to major products like Revlimid. Natco expects good earnings for the current and next year but foresees significant volatility post-March 2027 due to Revlimid price erosion, potentially leading to a 50-60% drop in earnings around that time.
From Natco Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a good year ahead with strong growth this and next year, despite volatility related to major products like Revlimid.
- Revenue from Revlimid will see a one-third quantity allocation starting March, impacting quarterly sales distribution.
- Domestic launches like Semaglutide (expected March 2026) and possibly Risdiplam (subject to favorable court verdict) are expected to drive growth in India.
- Emerging markets (ROW) and Canada businesses are expected to perform well with multiple approvals anticipated.
- Agrochemical (Crop Sciences) business targets doubling sales from ~60 crores to 120-150 crores next year aiming for breakeven.
2 more points from Natco Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Natco Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Natco Pharma is actively looking for acquisitions to deploy its cash reserves, targeting geography-based expansions primarily:
- One acquisition to strengthen the U.S. front-end portfolio.
- Another acquisition to bolster the Rest of World (ROW) business outside advanced regulated markets.
- The company prefers preserving cash for acquisitions rather than distributing high dividends or buybacks.
- They are considering both cash and debt as financing options for takeovers.
- No specific ongoing capex or expansion plans for manufacturing were discussed, but there is an understanding that acquiring a front-end manufacturing facility in the U.S. could be a strategic move.
2 more points from Natco Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Natco Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Natco Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Natco Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natco Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Natco Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natco Pharma Ltd Q3 FY25 results?
The company expects a good year ahead with strong growth this and next year, despite volatility related to major products like Revlimid. Natco expects good earnings for the current and next year but foresees significant volatility post-March 2027 due to Revlimid price erosion, potentially leading to a 50-60% drop in earnings around that time.
What is Natco Pharma Ltd share price analysis?
Natco Pharma Ltd currently shows a neutral. The stock trades at a P/E of 11.6 with a market cap of ₹16,434 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natco Pharma Ltd planning capital expenditure?
Natco Pharma is actively looking for acquisitions to deploy its cash reserves, targeting geography-based expansions primarily: - One acquisition to strengthen the U.S.
Keep Natco Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.